Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 6/20 | 0.48 |
| ▸ | FNTB | P49356 | 6/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867910 | 0.90 | POLB (0.47) | CYP19A1FNTAFNTBPGGT1BPOLB | |
| SCHEMBL20278917 | 0.89 | MAOB (0.49) | CYP19A1FNTAFNTBPGGT1BPOLB | |
| SCHEMBL17752288 | 0.88 | FNTA (0.57) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL26936315 | 0.85 | FNTA (0.49) | CYP19A1FNTAFNTBPGGT1BPOLB | |
| SCHEMBL21327476 | 0.83 | POLB (0.61) | CYP19A1FNTAFNTBPGGT1BPOLB | |
| SCHEMBL11802368 | 0.82 | CYP19A1 (0.67) | CYP19A1FNTAFNTBPGGT1BPOLB | |
| SCHEMBL7074501 | 0.82 | CYP19A1 (0.48) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL19642401 | 0.81 | MAPK1 (0.46) | CYP19A1FNTAFNTBPGGT1BPOLB | |
| SCHEMBL19474591 | 0.81 | CYP19A1 (0.47) | CYP19A1FNTAFNTBPGGT1BPOLB | |
| SCHEMBL5112608 | 0.80 | POLB (0.49) | CYP19A1FNTAFNTBPGGT1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9685615-B2 | Light emitting material, delayed fluorescent emitter, organic light emitting device, and compound | KYULUX, INC. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9685615-B2 | Light emitting material, delayed fluorescent emitter, organic light emitting device, and compound | KYULUX, INC. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20160141516-A1 | LIGHT EMITTING MATERIAL, DELAYED FLUORESCENT EMITTER, ORGANIC LIGHT EMITTING DEVICE, AND COMPOUND | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160141516-A1 | LIGHT EMITTING MATERIAL, DELAYED FLUORESCENT EMITTER, ORGANIC LIGHT EMITTING DEVICE, AND COMPOUND | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1833825-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007030089-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006069277-A1 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
| EP-1644373-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-12 | — | — | EP | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
| WO-2005003131-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CYP19A1 873/4885FNTA 2043/4885FNTB 1580/4885 |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | CYP19A1 873/4885FNTA 2043/4885FNTB 1580/4885 |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CYP19A1 873/4885FNTA 2043/4885FNTB 1580/4885 |
| US-20160141516-A1 | LIGHT EMITTING MATERIAL, DELAYED FLUORESCENT EMITTER, ORGANIC LIGHT EMITTING DEVICE, AND COMPOUND | CRY2, CRY1, IK | CYP19A1 1257/4885FNTA 4576/4885FNTB 4615/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CYP19A1 873/4885FNTA 2043/4885FNTB 1580/4885 |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CYP19A1 873/4885FNTA 2043/4885FNTB 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.